Short answer
Prime Medicine, Inc. (PRME) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$42M
- +19.9% YoY · +14.3% QoQ
- EPS (diluted)
- −$0.23
- +43.9% YoY · +17.9% QoQ
Source: XBRL data from the Prime Medicine, Inc. (PRME) Q2 2026 10-Q on SEC EDGAR. USD.
Prime Medicine, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New collaborator risk triggered by Beam arbitration over PM647 and AATD program scope
- Beam arbitration resolved July 6, 2026, declaring PM647 within Prime’s Field and denying Beam damages and injunctive relief
- Regulatory and compliance exposure from Broad Institute march-in rights covering all gene targets
- Operational dependence on third-party licensors controlling prosecution and maintenance of Prime’s key patents
- Competitive risk from nonexclusive licenses allowing third parties access to Prime Editing technology
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Prime Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.